NIKKEI 225
26,107.65 -315.82 (-1.20%) HANG SENG
21,586.66 -266.41 (-1.22%) CRUDE OIL
96.29 -3.21 (-3.23%) GOLD FUTURES
1,731.60 -32.30 (-1.83%) DOW
30,840.46 -127.36 (-0.41%) BTC-GBP
16,930.52 +417.08 (+2.53%)
LH Jan 2023 90.000 call
| Previous close | 195.50 |
| Open | 195.50 |
| Bid | 185.50 |
| Ask | 190.50 |
| Strike | 90.00 |
| Expiry date | 2023-01-20 |
| Day's range | 195.50 - 195.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
- Business Wire
Labcorp First National Laboratory to Offer Monkeypox Test
BURLINGTON, N.C., July 06, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox. This effort is part of the Administration’s commitment to quickly increase monkeypox testing access and capacity in every community during the ongoing outbreak.
- Zacks
LabCorp (LH) to Strengthen Laboratory Footprint in Japan
LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.
- Business Wire
Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration
BURLINGTON, N.C., June 28, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.
